Palbociclib (Ibrance)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 01:18, 23 December 2014 by Jwarner (talk | contribs) (Created page with "==Mechanism of action== Orally bioavailable cyclin-dependent kinase 4/6 inhibitor. ==Preliminary data== # Vaughn DJ, Hwang W, Lal P, Rosen MA, Gallagher M, O'Dwyer PJ. Phase ...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Mechanism of action

Orally bioavailable cyclin-dependent kinase 4/6 inhibitor.

Preliminary data

  1. Vaughn DJ, Hwang W, Lal P, Rosen MA, Gallagher M, O'Dwyer PJ. Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors. Cancer. 2014 Dec 18. [Epub ahead of print] link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Palbociclib_(Ibrance)&oldid=6475"